An experimental drug for treating Alzheimer’s disease has successfully slowed cognitive decline in a trial. The drug makers, Japan-based Eisai and US-based Biogen, said the drug may carry a risk of dangerous side effects for certain patients, including brain swelling and micro-haemorrhages. The companies are seeking approval in the US, Europe and Japan.
